Oxaprozin: Kinetic and dynamic profile in the treatment of pain

Current Medical Research and Opinion

Volumn 20, Issue 8, 2004, Pages 1275-1277

  Kean, Walter F ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

Inflammation; Musculoskeletal; Oxaprozin; Pain

Indexed keywords

ACETYLSALICYLIC ACID; ANTIRHEUMATIC AGENT; CANNABINOID; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDOMETACIN; METALLOPROTEINASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXAPROZIN;

ANALGESIA; ANKYLOSING SPONDYLITIS; CONSTIPATION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; FEVER; GASTROINTESTINAL SYMPTOM; HUMAN; INFLAMMATION; NAUSEA; OSTEOARTHRITIS; PAIN; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; TOOTH PAIN; TOXICITY; VOMITING;

EID: 4344700685     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904125004420     Document Type: Review

References (16)

1. Rainsford KD, Omar H, Ashraf A, Hewson AT, Bunning RAD, Rishiraj R. Recent pharmacodynamic and pharmacokinetic findings on oxaprozin. Inflamopharmacol 2002;10:185-239
2. Kean WF, Kean R, Buchanan WW. A critical assessment of oxaprozin clinical profile in rheumatic diseases. Inflammopharmacology 2002;10:241-284
3. Davies NM. Clinical pharmacokinetics of oxaprozin. Clinical Pharm 1998;35:42-36
4. Zinny MA. The effects of age and sex on oxaprozin single-dose and multiple-dose pharmacokinetics. Drug Ther 1993;23:37-45
5. Heller B, Tarricone R. Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder. Curr Med Res Opin 2004;20(8),DOI:10.1185/ 030079904125004411
6. Kean WF, Kean R, Buchanan WW. Osteoarthritis: symptoms, signs, and source of pain. Inflammopharmacology 2004;12:3-31
7. Forrest JB. Pathophysiology of acute pain. In: Forrest J, editor. Acute Pain: Pathophysiology and Treatment. Grimsby, ONT: Manticore 1998;31-65
8. Forrest JB. Sympathetic mechanisms in post operative pain. Can J Anaesth 1992;39:523-527
9. Konttinen YT, Kemppinen P, Segerberg M, et al. Peripheral and spinal neural mechanisms in arthritis, with particular reference to treatment of inflammation and pain. Arthritis Rheum 1994;37:965-982
10. Todd PA, Brogden RN. Oxaprozin: A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. Drugs 1986;32:291-312
11. Dallegri F, Ottonello L. Pharmacological implications in the switch from acute to chronic inflammation. Inflammopharmacol 2002;10:159-171
12. Bevilacqua M. Effects of oxaprozin and of other 2-arylpropionic acid derivatives on Nuclear Factor κB(NF-κB) activation. Inflammopharmacol 2002;10:173-183
13. Baracchini A, Minisola G, Amicosante G, Franceschini N. Oxaprozin: a NSAID able to inhibit the matrix metalloproteinase activity. Inflammopharmacology 2001;9:143-146
14. Ritchlin C. Fibroblast biology. Effector signals released by synovial fibroblast in arthritis. Arthritis Res 2000;2;356-360
15. Piomelli D, Giuffrida A, Calignano A, Rodriguez de Fonseca F. The cannabinoid system as a target for therapeutic drugs. TiPS 2000;21:218-224
16. Bevilacqua M. Pharmacology of oxaprozin: novel findings. In: Oxaprozin and the daily management of osteomuscular impairment in arthritic patients. Highlights from the Satellite Symposium on Oxaprozin at the XIV EULAR Congress, Adis International, Milan, Italy 2000;pp.3-6